Dear reader of ADxS.org, please excuse the disruption.

ADxS.org needs about $63500 in 2024. In 2023 we received donations of about $ 32200. Unfortunately, 99.8% of our readers do not donate. If everyone who reads this request makes a small contribution, our fundraising campaign for 2024 would be over after a few days. This donation request is displayed 23,000 times a week, but only 75 people donate. If you find ADxS.org useful, please take a minute and support ADxS.org with your donation. Thank you!

Since 01.06.2021 ADxS.org is supported by the non-profit ADxS e.V..

$8975 of $63500 - as of 2024-02-29
14%
Header Image
L-theanine for ADHD

Sitemap

L-theanine for ADHD

Theanine (L-theanine, 5-N-ethyl-L-glutamine, delta-glutamylethylamide; gamma-glutamylethylamide) is an amino acid found in green tea.1
Theanine crosses the blood-brain barrier.2

1. Neurophsiological effect of theanine

L-theanine has a neurophysiological effect as:

  • Glutamate reuptake inhibitors3
    • Theanine has a strong effect on the glutamine transporter and inhibits glutamine reuptake, which in turn suppresses the conversion of glutamine into glutamate by glutaminase.2
  • competitive low-affinity glutamate receptor antagonist in the hippocampus3
    • very weakly antagonistic to glutamate AMPA and glutamate kainate receptors.2
  • binds to GABA-A receptors3
  • increased gene expression with a large effect size4
    • in the hippocampus
      • EGR1 (Early growth response protein 1; also ZNF268 = Zinc finger protein 268 or NGFI-A = Nerve growth factor-induced protein A)
      • MAO-A (monoamine oxidase A; breaks down serotonin, dopamine and noradrenaline)
      • ANXA9 (Annexin A9)
      • S100a10 (Calcium-binding protein A10; P11)
      • GABRB2 (GABA-A receptor beta-2 subunit)
      • CHRM2 (muscarinic acetylcholine receptor M2)
    • in the amygdala
      • GABRA4 (GABA-A receptor alpha-4 subunit)
      • SLC5A7 (high-affinity choline transporter; solute carrier family 5 member 7)
      • DRD2 (D2 dopamine receptor gene)
      • DRD1a (D1a dopamine receptor gene)
      • GLRA2 (glycine receptor alpha 2)
      • CHRNA6 (nicotinic receptor / choline receptor alpha 6)
      • HTR3A (serotonin 3A receptor)
      • CHRNB4 (nicotinic receptor / choline receptor beta 4)
      • GABRD (GABA-A receptor subunit delta)
      • PRIMA1 (Proline Rich Membrane Anchor 1)
      • CHRNA3 (nicotinic receptor / choline receptor alpha 3)

L-theanine is safe in daily doses of 200 to 400 mg over a period of up to 8 weeks.5

2. Behavioral effect of theanine

Theanine has a calming and relaxing effect,6 also better than the benzodiazepine alprazolam, but not anxiolytic.7 According to other studies, theanine has an anxiolytic and stress-inhibiting effect,5 although the anxiolytic effect does not appear to be due to an effect on the GABA-A receptor.8
Caffeine and gallate catechins, which are abundant in tea, inhibit the relaxing effect of theanine.9

Theanine inhibited the deterioration of cognitive functions in older people2 and could have neuroprotective effects to prevent Parkinson’s disease.10

L-theanine administration promoted the release of dopamine and noradrenaline in the hippocampus of mice and stimulated protein kinase A (PKA) phosphorylation. The long-term potentiation in the hippocampus improved by L-theanine in an Alzheimer’s mouse model could be impaired by a PKA inhibitor. L-theanine probably improves memory and long-term potentiation in the hippocampus of Alzheimer’s mice via the dopamine D-1/D-5 receptor PKA pathway. L-theanine could be considered as a candidate for the treatment of Alzheimer’s disease.11

Theanine counteracted a caffeine-induced increase in blood pressure, but had no effect on mood.12

3. L-theanine for ADHD

Apparently, theanine increases the dopamine level in the striatum. Except for improved learning abilities, the behavior of the mice that received theanine for 3 months was unchanged.13

Direct administration of theanine into the striatum of mice significantly increased dopamine in a dose-dependent manner. The increase in dopamine was attenuated by a previously administered calcium-free ring buffer. If the ring buffer also contained the non-NMDA glutamate receptor antagonist MK-801, the significant increase in dopamine due to L-theanine was maintained. When an NMDA glutamate receptor antagonist was given instead, this significantly inhibited theanine-induced dopamine release in the striatum. Theanine altered the concentrations of noradrenaline, 3,4-dihydroxyphenylacetic acid (DOPAC) and 5-hydroxyindoleacetic acid (5HIAA) only in the striatum, but not in other brain regions.
Theanine caused a significant increase in serotonin and dopamine in the brain, particularly in the striatum, hypothalamus and hippocampus.14

A very small study on 5 boys with ADHD investigated the effect of L-theanine (2.5 mg/kg) and caffeine (2.0 mg/kg) (alternative, combined and placebo):15

L-theanine alone

  • improved overall cognition
  • tend to worsen inhibitory control (increased stop-signal response time)

Caffeine alone

  • worsens inhibitory control

L-theanine and caffeine combined

  • improved overall cognitive performance
  • improved the signal sensitivity to the Go signal (the d-prime in the Go/NoGo task)
  • tended to improve inhibitory control
  • reduced the task-related reactivity of the default mode network associated with mind wandering

A randomized placebo-controlled study found improved directed attention with L-theanine and even more with a combination of L-theanine and caffeine.16

400 mg L-theanine (200 mg each in the morning and at noon) improved sleep quality in a randomized, double-blind, placebo-controlled study in boys with ADHD. Actigraph measurements showed a significantly higher percentage of sleep and sleep efficiency achieved, along with a non-significant trend towards less activity during sleep. Sleep latency and other sleep parameters remained unchanged. No significant adverse events occurred.17

There is no research on the use of L-theanine in relation to other ADHD symptoms.


  1. Alramadhan, Hanna, Hanna, Goldstein, Avila, Weeks (2012): Dietary and botanical anxiolytics. Med Sci Monit. 2012 Apr;18(4):RA40-8.

  2. Kakuda (2011): Neuroprotective effects of theanine and its preventive effects on cognitive dysfunction. Pharmacol Res. 2011 Aug;64(2):162-8. doi: 10.1016/j.phrs.2011.03.010.

  3. Anas Sohail, Ortiz, Varghese, Fabara, Batth, Sandesara, Sabir, Khurana, Datta, Patel (2021): The Cognitive-Enhancing Outcomes of Caffeine and L-theanine: A Systematic Review. Cureus. 2021 Dec 30;13(12):e20828. doi: 10.7759/cureus.20828. PMID: 35111479; PMCID: PMC8794723. REVIEW

  4. Ceremuga, Martinson, Washington, Revels, Wojcicki, Crawford, Edwards, Kemper, Townsend, Herron, Ceremuga, Padron, Bentley (2014)_- : Effects of L-theanine on posttraumatic stress disorder induced changes in rat brain gene expression. ScientificWorldJournal. 2014;2014:419032. doi: 10.1155/2014/419032. PMID: 25165739; PMCID: PMC4137547.

  5. Lopes Sakamoto, Metzker Pereira Ribeiro, Amador Bueno, Oliveira Santos (2019): Psychotropic effects of L-theanine and its clinical properties: From the management of anxiety and stress to a potential use in schizophrenia. Pharmacol Res. 2019 Sep;147:104395. doi: 10.1016/j.phrs.2019.104395. PMID: 31412272. REVIEW

  6. Weeks (2009): Formulations of dietary supplements and herbal extracts for relaxation and anxiolytic action: Relarian. Med Sci Monit. 2009 Nov;15(11):RA256-62.

  7. Lu, Gray, Oliver, Liley, Harrison, Bartholomeusz, Phan, Nathan (2004): The acute effects of L-theanine in comparison with alprazolam on anticipatory anxiety in humans. Hum Psychopharmacol. 2004 Oct;19(7):457-65.

  8. Heese, Jenkinson, Love, Milam, Perkins, Adams, McCall, Ceremuga (2009): Anxiolytic effects of L-theanine–a component of green tea–when combined with midazolam, in the male Sprague-Dawley rat. AANA J. 2009 Dec;77(6):445-9.

  9. Unno, Yamada, Iguchi, Ishida, Iwao, Morita, Nakamura (2017): Anti-stress Effect of Green Tea with Lowered Caffeine on Humans: A Pilot Study. Biol Pharm Bull. 2017;40(6):902-909. doi: 10.1248/bpb.b17-00141. PMID: 28566632.

  10. Cho, Kim, Lee, Park, Kim, Chun (2008): Protective effect of the green tea component, L-theanine on environmental toxins-induced neuronal cell death. Neurotoxicology. 2008 Jul;29(4):656-62. doi: 10.1016/j.neuro.2008.03.004.

  11. Zhu, Yang, Xie, Wan (2018): Synaptic modification by L-theanine, a natural constituent in green tea, rescues the impairment of hippocampal long-term potentiation and memory in AD mice. Neuropharmacology. 2018 Aug;138:331-340. doi: 10.1016/j.neuropharm.2018.06.030.

  12. Rogers, Smith, Heatherley, Pleydell-Pearce (2008): Time for tea: mood, blood pressure and cognitive performance effects of caffeine and theanine administered alone and together. Psychopharmacology (Berl). 2008 Jan;195(4):569-77.

  13. Yokogoshi, Terashima (2000): Effect of theanine, r-glutamylethylamide, on brain monoamines, striatal dopamine release and some kinds of behavior in rats. Nutrition. 2000 Sep;16(9):776-7.

  14. Yokogoshi, Kobayashi, Mochizuki, Terashima (1998): Effect of theanine, r-glutamylethylamide, on brain monoamines and striatal dopamine release in conscious rats. Neurochem Res. 1998 May;23(5):667-73.

  15. Kahathuduwa, Wakefield, West, Blume, Dassanayake, Weerasinghe, Mastergeorge (2020): Effects of L-theanine-caffeine combination on sustained attention and inhibitory control among children with ADHD: a proof-of-concept neuroimaging RCT. Sci Rep. 2020 Aug 4;10(1):13072. doi: 10.1038/s41598-020-70037-7. PMID: 32753637; PMCID: PMC7403383.

  16. Kahathuduwa, Dhanasekara, Chin, Davis, Weerasinghe, Dassanayake, Binks (2018): l-Theanine and caffeine improve target-specific attention to visual stimuli by decreasing mind wandering: a human functional magnetic resonance imaging study. Nutr Res. 2018 Jan;49:67-78. doi: 10.1016/j.nutres.2017.11.002. Epub 2017 Nov 16. PMID: 29420994.

  17. Lyon, Kapoor, Juneja (2011): The effects of L-theanine (Suntheanine®) on objective sleep quality in boys with attention deficit hyperactivity disorder (ADHD): a randomized, double-blind, placebo-controlled clinical trial. Altern Med Rev. 2011 Dec;16(4):348-54. PMID: 22214254.

Diese Seite wurde am 19.03.2024 zuletzt aktualisiert.